The Cancer Letter

Inside information on cancer research and drug development

In Brief

NCCN begins work on guidelines to improve cancer care in the Caribbean

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Comprehensive Cancer Network and the Caribbean Association for Oncology & Hematology are collaborating to develop a library of NCCN Harmonized Guidelines for the Caribbean during the CAOH Conference—Oncology.

Robert Carlson, chief executive officer of NCCN was joined at the CAOH conference by Joan McClure, senior vice president, clinical information and publications, NCCN; Ben Anderson, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; Al Benson, Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Natalie Callander, University of Wisconsin Carbone Cancer Center; Wui-Jin Koh, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; James Mohler, Roswell Park Comprehensive Cancer Center; and Douglas Wood, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

They participated in a working session with local oncologists to adapt existing NCCN Clinical Practice Guidelines in Oncology and NCCN Framework for Resource Stratification of NCCN Guidelines in order to better reflect the diverse needs and resources throughout the Caribbean.

The Clinical Team was led by Kavi Capildeo, Trinidad and Tobago; Sophia Edwards-Bennett, Jamaica; Owen Gabriel, St. Lucia; Theresa Laurent, Oncology/Haematology, Barbados; Dylan Narinesingh; and Gilian Wharfe, The University of the West Indies, Jamaica.

The NCCN Harmonized Guidelines for the Caribbean will initially cover the following cancer types:

  • Breast Cancer

  • Cervical Cancer

  • Colon Cancer & Colon Cancer Screening

  • Multiple Myeloma

  • Non-Small Cell Lung Cancer

  • Prostate Cancer

  • Rectal Cancer

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account